AstraZeneca Hits New 52-Week High at $60.59 (AZN)
Shares of AstraZeneca (NYSE:AZN) hit a new 52-week high on Friday, Analyst Ratings.Net reports. The company traded as high as $60.59 and last traded at $60.51, with a volume of 2,121,512 shares trading hands. The stock had previously closed at $59.37.
A number of research firms have recently commented on AZN. Analysts at UBS AG initiated coverage on shares of AstraZeneca in a research note to investors on Thursday. They set a “buy” rating on the stock. Separately, analysts at Jefferies Group upgraded shares of AstraZeneca from an “underperform” rating to a “hold” rating in a research note to investors on Thursday. Finally, analysts at Zacks reiterated a “neutral” rating on shares of AstraZeneca in a research note to investors on Monday. They now have a $62.00 price target on the stock. Five equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the stock. AstraZeneca presently has an average rating of “Hold” and a consensus target price of $56.80.
AstraZeneca has a 1-year low of $44.46 and a 1-year high of $59.67. The stock’s 50-day moving average is $57.61 and its 200-day moving average is $52.38. The company has a market cap of $75.819 billion and a price-to-earnings ratio of 16.01.
AstraZeneca (NYSE:AZN) last announced its earnings results on Thursday, October 31st. The company reported $1.21 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.27 by $0.06. The company had revenue of $6.25 billion for the quarter, compared to the consensus estimate of $6.45 billion. During the same quarter in the prior year, the company posted $1.51 earnings per share. The company’s quarterly revenue was down 6.5% on a year-over-year basis. On average, analysts predict that AstraZeneca will post $5.07 earnings per share for the current fiscal year.
AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.